Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.78T
24h Vol:
$10.16B
Dominance:
MSFT:4.81%
Stocklytics Platform
Asset logo  TFFP
TFF Pharmaceuticals
TFFP
73 / 100
High Growth
Penny Stock
$2.24arrow_drop_down2.18%-$0.05

Performance History

Stocklytics logo
Key Stats
Open$2.28
Prev. Close$2.29
EPS-11.85
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap7094717.00
PE Ratio-
LOWHIGH
Day Range2.07
2.39
52 Week Range1.54
16.85
Ratios
P/B Ratio1.01
Revenue-
Operating M. %-4,695.88%
Earnings$0.00
Earnings Growth %33.13%
EBITDA Margin %-
ROE %-130.94%
EPS-11.85

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$803.16
24H (%)arrow_drop_up2.55%
24H ($)$19.98
MARKET CAP$744.33B
PRICE$523.54
24H (%)arrow_drop_up1.22%
24H ($)$6.32
MARKET CAP$476.05B
PRICE$151.24
24H (%)arrow_drop_down0.01%
24H ($)-$0.03
MARKET CAP$364.05B
PRICE$130.75
24H (%)arrow_drop_down0.17%
24H ($)-$0.23
MARKET CAP$332.27B

About TFF Pharmaceuticals (TFFP)

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Harlan F. Weisman
Headquarters
Fort Worth
Employees
15
Exchange
NASDAQ
add TFF Pharmaceuticals  to watchlist

Keep an eye on TFF Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is TFF Pharmaceuticals 's (TFFP) price per share?

The current price per share for TFF Pharmaceuticals (TFFP) is $2.24. The stock has seen a price change of -$0.05 recently, indicating a -2.18% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for TFF Pharmaceuticals (TFFP)?

For TFF Pharmaceuticals (TFFP), the 52-week high is $16.85, which is 652.23% from the current price. The 52-week low is $1.54, the current price is 45.45% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is TFF Pharmaceuticals (TFFP) a growth stock?

TFF Pharmaceuticals (TFFP) has shown an average price growth of 0.41% over the past three years. It has received a score of 95 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying TFF Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is TFF Pharmaceuticals (TFFP) stock price performance year to date (YTD)?

As of the latest data, TFF Pharmaceuticals (TFFP) has a year-to-date price change of -67.58%. Over the past month, the stock has experienced a price change of -13.18%. Over the last three months, the change has been -66.16%. Over the past six months, the figure is -68.11%.

help
Is TFF Pharmaceuticals (TFFP) a profitable company?

TFF Pharmaceuticals (TFFP) has a net income of -$21.24M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 31.53% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -4.7K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $231.39K. Operating income is noted at -$22.63M. Furthermore, the EBITDA is -$21.39M.

help
What is the market capitalization of TFF Pharmaceuticals (TFFP)?

TFF Pharmaceuticals (TFFP) has a market capitalization of $7.09M. The average daily trading volume is 50.73K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level